This is the first book to present the beneficial effects of hydrogen sulfide in the treatment of various kidney pathologies. Hydrogen sulfide (H2S), a gas with a distinctive smell of rotten eggs, was known for over three centuries for its toxicity and death at high concentrations especially among agricultural and industrial workers. This is due to its ability to reversibly antagonize complex IV of the mitochondrial electron transport chain. However, studies over the past two decades have shown that H2S has risen above its historic notorious label and has received significant experimental attention as an endogenously produced gaseous signaling molecule that plays an important role in cellular homeostasis and influences a myriad of physiological and pathological processes at low concentrations. Its production is enzymatically regulated and has specific molecular targets. Several recentin vitro andin vivo studies have demonstrated that at low micromolar concentrations, H2S exhibits important therapeutic characteristics that target multiple molecular pathways and thereby preventing the development and progression of several pathologies.

This beneficial effect of H2S suggests that it may meet the demand for alternative and/or additional therapeutic agents against various renal pathologies in which reduced levels of renal and plasma H2S were observed. Interestingly, while the distribution of H2S-producing enzymes is tissue-specific, they are abundantly expressed in the glomeruli and in the brush border and cytoplasm of epithelial cells of the renal tubules and in the peritubular capillaries. This makes the kidney a rich source of endogenous H2S production. From pre-clinical and clinical perspectives, this book is topical and timely, and seeks to lay the foundation for future clinical applications of H2S in nephrology.

George Johnson Dugbartey (BSc, MSc, PhD) is a faculty member of University of Ghana, where he teaches Physiology and Pharmacology at undergraduate and graduate levels. He is also a Research Associate in surgery at London Health Sciences Centre, University of Western Ontario, Canada, where his research focuses on hydrogen sulfide in kidney transplantation. In addition, his research areas also include hydrogen sulfide therapy for diabetic and hypertensive nephropathies, and drug-induced acute kidney injury. He has over 10 years of research experience in the hydrogen sulfide field. Dr. Dugbartey is a well-traveled scholar, educator, and a versatile scientist, and has presented his research findings at a lot of scientific conferences globally. He is also the recipient of several

conference awards and research awards including the prestigious Canadian Institutes of Health Research Grant Award. He has about 50 publications in internationally reputable peer-reviewedjournals, most of which he is the lead author.

Alp Sener (BA, MD, PhD, FRCSC) is the Chief and Chair of Urology and Director of Kidney and Pancreas Transplant Fellowship Program at Schulich School of Medicine and Dentistry, London Health Sciences Centre and St. Josephs Hospital, London, Canada. He is an accomplished researcher, with over 20 years of research experience in the areas of kidney transplantation and hydrogen sulfide as a novel pharmacological approach for improved renal graft preservation. Dr. Sener is an internationally recognized kidney transplant surgeon, educator and researcher, with about 200 publications comprising research papers, reviews, conference abstracts and book chapters. He has presented his research findings in many national and international conferences. He is also a

recipient of several prestigious local, national and international research contribution awards including the Canadian Society of Transplantation Research Excellence Award, Western University Deans Award of Excellence, and Vanguard Award from the American Society of Transplant Surgeons.

Chapter 1: Hydrogen Sulfide and the Renal System.-Chapter 2: Hydrogen Sulfide for Cisplatin-Induced Acute Kidney Injury.-Chapter 3:Hydrogen Sulfide as a Therapeutic Alternative for Chronic Kidney Disease.-Chapter 4:Hydrogen Sulfide in Diabetic Kidney Disease.-Chapter 5:Hydrogen Sulfide for the Treatment of Hypertensive Nephropathy.-Chapter 6:Hydrogen Sulfide as a Potential Therapy for COVID-19-Associated Nephropathy.-Chapter 7:Hydrogen Sulde as a Potential Novel Therapy to Prevent Renal Damage During Ureteral Obstruction.-Chapter 8:Hydrogen Sulfide Therapy as the Future of Renal Graft Preservation.-Chapter 9:Hydrogen Sulfide against Ischemia-Reperfusion Injury in Transplantation of Kidney and Other Transplantable Solid Organs.-Chapter 10:FDA-Approved Hydrogen Sulfide Donor Drug and its Clinical Applications in Nephrology.